ORO Labs Named Top Procurement Technology Provider at 2025 World Procurement Awards
SAN FRANCISCO--(BUSINESS WIRE)-- ORO Labs, the market's leading enterprise-grade intake management and procurement orchestration platform, has been named the winner of the Procurement Technology Provider Award at the 2025 World Procurement Awards.
Hosted annually by Procurement Leaders, the awards celebrate the individuals, teams, and companies setting new benchmarks for innovation, performance, and impact across the global procurement function. ORO was selected for its AI-powered orchestration platform, which delivers intuitive user experiences and enables businesses to shorten cycle times, reduce risk through end-to-end process visibility, and stay agile with a platform specifically designed for procurement teams.
'Procurement touches every corner of business operations, yet it's often slowed down by manual, fragmented systems that make it hard to move at the speed organizations actually need,' said Sudhir Bhojwani, Co-Founder and CEO of ORO. 'We built ORO to cut through that friction — to give teams what they need, without frustration. This award is a meaningful validation that when procurement is connected, agile, and user-first, it becomes one of the most powerful drivers of business impact.'
ORO's platform simplifies the source-to-pay process by connecting systems, people, and policies across the enterprise. Designed for scale, it helps teams automate compliance, streamline workflows, and adapt in real time to changing business needs, without losing control or visibility. In a year defined by rapid market and regulatory change, AI acceleration, and global supply chain disruption, ORO is helping leading enterprises move faster, stay compliant, and navigate change with confidence – a challenge Bayer, a global life sciences leader, is tackling head-on with ORO.
'ORO is a true AI innovation partner helping us work toward our vision of a zero-bureaucracy experience,' said Thomas Udesen, CPO at Bayer.
The award follows a year of strong growth and recognition for ORO, including the acquisition of ProcureTech, leadership in Spend Matters' 2025 SolutionMap for Intake and Orchestration and in IDC's inaugural MarketScape, and several award wins from Supply & Demand Chain Executive. To learn more, visit orolabs.ai.
About ORO Labs
ORO Labs is a procurement orchestration company on a mission to humanize the procurement experience by coordinating teams, systems, and processes so employees get what they need without frustration. ORO's AI-powered no-code platform is purpose-built to deliver effortless user experiences that enable businesses to reduce cycle times, decrease risk through end-to-end process visibility, and increase agility in response to change. ORO is trusted by Fortune 500 companies and fast-growing global organizations to automate processes, improve cross-team collaboration, and scale procurement operations. To learn more, visit orolabs.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
How to Organize a Health Technology Business with Focus on 10+ Organizational Archetypes
Discover the evolving organizational structures of digital health businesses in the Pharma and MedTech sectors. This report analyzes 11 HealthTech archetypes over 15 years, offering insights on performance across key KPIs, future trends, and strategic recommendations. Featured companies include Bayer, Roche, and more. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "How to Organize a HealthTech Business?" report has been added to offering. This report sheds light on how to organize digital health businesses, especially at large Pharma and MedTech companies. By looking at how other companies have been managing their HealthTech businesses over the last 15 years, 11 different HealthTech organizational archetypes are being detailed out in the report, including their objectives, responsibilities, team sizes, target partner company stages, governance, value propositions for their partners, business impact evaluations across 4 KPIs and real-life examples from companies who had deployed these structures. Performance of the 11 archetypes are then evaluated and compared across the four main KPIs which are based on finding partners, launching solutions, driving usages & cultural change support. Based on the evaluation of the success and impact of these archetypes, the report presents a benchmarking table of HealthTech business organizations today. With a deep-dive into the evolving trends in HealthTech business organizations responding to the changing market conditions across three main market phases, 5 trend points for future and relevant recommendations are provided on what needs to be done to stay competitive and move forward in growing digital health market. Questions the report answers: What are the archetypes to organize HealthTech businesses at Pharma and MedTech companies? What are the different objectives and responsibilities of each organizational archetype? How are the archetypes governed at larger corporates? How does each organizational archetype perform? Which Pharma and MedTech apply which archetype to manage their HealthTech business today? How did the archetypes evolve to adept the market conditions today? What does the market require for organization of HealthTech businesses in 3-5 years? Interested parties can benefit from this report in the following ways: Consultants: gain insights into different organizational structures within the HealthTech industry, and enhance the ability to advise clients on optimal structuring and strategic alignment for digital health initiatives Strategy heads: understand how leading organizations structure their HealthTech initiatives, which can inform strategic planning and decision-making processes Business unit heads: understand how to integrate digital health solutions into the units effectively, determine the most suitable structure for the unit, and align with overall corporate objectives Digital health unit heads: benchmark your organizational structure against others, know what is needed in terms organizational structure to stay competitive in the growing digital health market, and optimize your organizational structure to foster innovation and integration with business units In this report, the following companies are mentioned: Bayer Roche Biogen Sanofi Siemens Healtineers GE Healthcare Janssen (J&J) MSD Merck KGaA Novartis Becton Dickenson and Company *30 min report consultation with a research analyst available with the purchase of an enterprise license Key Topics Covered: Archetype-1: Central Teams Archetype-2: De-Central Teams Archetype-3: Carve-Outs Archetype-4: Innovation Hubs Archetype-5: Incubators Archetype-6: Accelerators Archetype-7: Collaborative Accelerators Archetype-8: People Accelerators Archetype-9: Marketplace Organizations Archetype-10: Venture Funds Archetype-11: Outsourcing The Influence of Market Maturity on the Development of HealthTech Organizational Forms Building Successful HealthTech Teams for the Next 3-5 Years For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Soaring Gold Prices Draw Illicit Miners—and Armed Gangs—to Colombia's Jungles
PUERTO CLAVER, Colombia—The lure of even a few specks of gold compels Elizabeth Mosquera awake before dawn to slog to a muddy pit, where she wades into waist-deep water and starts to pan. 'What you earn in a month in a regular job, you can make here in an hour or two,' said Mosquera, 47 years old. In Colombia, the prospecting economy is driving revenue to drug-trafficking organizations that are already awash in proceeds from the record supplies of cocaine they are exporting to the U.S. and Europe, law-enforcement officials said.
Yahoo
2 days ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
